Position paper on the indications for the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis

被引：1
|
作者：
Brown, S. L. [1 ]
机构：
[1] Johannesburg Hosp, Div Endocrinol & Metab, Dept Med, Johannesburg, South Africa
来源：
JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA | 2009年 / 14卷 / 01期
关键词：
D O I：
10.1080/22201009.2009.10872192
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [1] Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis
    Hough, Stephen
    Ascott-Evans, Brynne
    de Villiers, Tobie
    de Weerd, Jan
    Ellis, Graham
    Lipschitz, Stan
    [J]. JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA, 2005, 10 (02) : 51 - 53
  • [2] Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis
    Hough, S
    Ascott-Evans, B
    de Villiers, T
    de Weerd, J
    Ellis, G
    Lipschitz, S
    [J]. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2004, 94 (03): : 175 - 177
  • [3] Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis
    Pearson, Richard G.
    Masud, Tahir
    Blackshaw, Elaine
    Naylor, Andrew
    Hinchcliffe, Michael
    Jeffery, Kirk
    Jordan, Faron
    Shabir-Ahmed, Anjumn
    King, Gareth
    Lewis, Andrew L.
    Illum, Lisbeth
    Perkins, Alan C.
    [J]. PHARMACEUTICS, 2019, 11 (06):
  • [4] In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis
    Williams, Allan J.
    Jordan, Faron
    King, Gareth
    Lewis, Andrew L.
    Illum, Lisbeth
    Masud, Tahir
    Perkins, Alan C.
    Pearson, Richard G.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 535 (1-2) : 113 - 119
  • [5] A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis
    Feng, Jiao
    Liu, Yanhua
    Xing, Yun
    Wang, Huaqian
    Li, Taiming
    Liu, Jingjing
    Fan, Hao
    Cao, Rongyue
    [J]. PEPTIDES, 2009, 30 (06) : 1173 - 1180
  • [6] PTH (1-34): A novel anabolic drug for the treatment of osteoporosis
    Holick, MF
    [J]. SOUTHERN MEDICAL JOURNAL, 2005, 98 (11) : 1114 - 1117
  • [7] Teriparatide (biosynthetic human parathyroid hormone 1-34): A new paradigm in the treatment of osteoporosis
    Brixen, KT
    Christensen, PM
    Ejersted, C
    Langdahl, BL
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 94 (06) : 260 - 270
  • [8] Parathyroid hormone (PTH)-related protein(1-36) is equipment to PTH(1-34) in humans
    EverhartCaye, M
    Inzucchi, SE
    GuinnessHenry, J
    Mitnick, MA
    Stewart, AF
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (01): : 199 - 208
  • [9] A COMPARISON OF THE INVIVO BIOCHEMICAL RESPONSES TO EXOGENOUS PARATHYROID HORMONE-(1-34) [PTH-(1-34)] AND PTH-RELATED PEPTIDE-(1-34) IN MAN
    FRAHER, LJ
    HODSMAN, AB
    JONAS, K
    SAUNDERS, D
    ROSE, CI
    HENDERSON, JE
    HENDY, GN
    GOLTZMAN, D
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (02): : 417 - 423
  • [10] Teriparatide [human parathyroid hormone (1-34)] therapy in men with osteoporosis
    Kaufman, J. -M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S184 - S185
12345